A pancreatic ductal adenocarcinoma (PDAC) cachexia model was developed by generating a tumor cell line from genetically modified mice with oncogenic KRAS G12D mutation and additional tumor suppressor P53 R172H mutation, and subsequently implanting the cells in wild-type C57BL/6 mice either subcutaneously, intraperitoneally or orthotopically. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.